Company profile: Sevion Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical discovery, development, and acquisition of innovative therapeutic product candidates for cancer and immunological diseases, advancing a pipeline of proprietary and partnered candidates leveraging unique antibody technology platforms.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sevion Therapeutics
NBE Therapeutics
HQ: Switzerland
Website
- Description: Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NBE Therapeutics company profile →
VelosBio
HQ: United States
Website
- Description: Provider of clinical-stage, next-generation oncology therapeutics, developing first-in-class ROR1-directed treatments, including novel antibody-drug conjugates for hematologic and solid tumors; offerings include injection-based therapies such as WINREVAIR (sotatercept-csrk) and KEYTRUDA (pembrolizumab).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VelosBio company profile →
Xstrahl
HQ: United States
Website
- Description: Provider of superficial orthovoltage X-ray systems for treating skin and bone cancers, dermatological disorders, benign conditions, and for palliative care, with precise non-surgical options. Also offers a compact office-based dual-modality device for non-melanoma skin cancers and keloid scarring, and advanced X-ray platforms for preclinical radiation biology research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xstrahl company profile →
Immunicum
HQ: Sweden
Website
- Description: Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicum company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sevion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sevion Therapeutics
2.2 - Growth funds investing in similar companies to Sevion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sevion Therapeutics
4.2 - Public trading comparable groups for Sevion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →